Evaluation of quality of life following treatment with etoricoxib in patients with arthritis or low-back pain: an open label, uncontrolled pilot study in Mexico
Authors:
- Cesar R. Ramos-RemusCRCesar R. Ramos-Remus
- for the ProExp Study GroupFGfor the ProExp Study Group
- 5 March 2004
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 20 (5) , 691-698
Abstract
An open-label study was undertaken at multiple centers in Mexico to assess the impact of treatment with etoricoxib - a selective cyclo-oxygenase-2 (COX-2) inhibitor - on quality of life (QoL) and pain relief among patients with osteoarthritis (OA), rheumatoid arthritis (RA) or chronic low-back pain (CLBP). The study involved 191 adult patients (aged > 18years old) who had used non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of OA, RA or CLBP during the month prior to study enrolment. After discontinuation of prior therapy, patients were treated with etoricoxib 60 mg for OA and CLBP, or 90 mg for RA once daily for 2 weeks.Patient and physician questionnaires were used to collect information about drug treatments, patients' QoL (Short Form-8 Health Survey [SF-8™] and EQ-5D VAS), patients' pain assessment, and physicians' and patients' satisfaction with treatment at baseline and at follow-up visits.Relative to prior NSAID use, etoricoxib use was associated with improvements in ...Keywords
This publication has 9 references indexed in Scilit:
- Complementary studies of the gastrointestinal safety of the cyclo‐oxygenase‐2‐selective inhibitor etoricoxibAlimentary Pharmacology & Therapeutics, 2003
- Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritisBMJ, 2002
- A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]BMC Family Practice, 2002
- Patient and Physician Satisfaction with Rofecoxib in Osteoarthritis: Results of a Post-marketing Surveillance Study in Primary Care in GermanyCurrent Medical Research and Opinion, 2002
- The Biochemical Selectivity of Novel COX-2 Inhibitors in Whole Blood Assays of COX-isozyme ActivityCurrent Medical Research and Opinion, 2002
- Efficacy and Tolerability Profile of Etoricoxib in Patients with Osteoarthritis: A Randomized, Double-blind, Placebo and Active-comparator Controlled 12-Week Efficacy TrialCurrent Medical Research and Opinion, 2002
- Nutritional Status and Well Being. Is There a Relationship Between Body Mass Index and the Well-being of Older People?Current Medical Research and Opinion, 2001
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990